MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $175.14M |
| Gross Profit (TTM) | $-1.30M |
| EBITDA | $-32.17M |
| Operating Margin | -42.20% |
| Return on Equity | -225.90% |
| Return on Assets | -8.05% |
| Revenue/Share (TTM) | $2.76 |
| Book Value | $0.33 |
| Price-to-Book | 6.26 |
| Price-to-Sales (TTM) | 1.48 |
| EV/Revenue | 0.982 |
| EV/EBITDA | -1.54 |
| Quarterly Earnings Growth (YoY) | -70.40% |
| Quarterly Revenue Growth (YoY) | 378.00% |
| Shares Outstanding | $63.70M |
| Float | $57.01M |
| % Insiders | 3.42% |
| % Institutions | 77.64% |
Volatility is currently contracting
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress.
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MGNX and any ticker you trade — then tracks every position and per-strategy win rate.
